Identification

Name
Peginterferon alfa-2b
Accession Number
DB00022  (BTD00048, BIOD00048)
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Interferons
Description

Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [3]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2b. Peginterferon alfa-2b is derived from the alfa-2b moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway. Use of Peginterferon alfa-2b is associated with a wide range of severe adverse effects including the aggravation and development of endocrine and autoimmune disorders, retinopathies, cardiovascular and neuropsychiatric complications, and increased risk of hepatic decompensation in patients with cirrhosis. The use of Peginterferon alfa-2b has largely declined since newer interferon-free antiviral therapies have been developed.

In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) no longer recommend Peginterferon alfa-2b for the treatment of Hepatitis C [2]. Peginterferon alfa-2b was used alongside Ribavirin with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality [1].

Peginterferon alfa-2b is available as a variable dose injectable product (tradename Pegintron) used for the treatment of chronic Hepatitis C. Approved in 2001 by the FDA, Pegintron is indicated for the treatment of HCV with Ribavirin or other antiviral drugs [Label]. When combined together, Peginterferon alfa-2b and Ribavirin have been shown to achieve a SVR between 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment.

Protein structure
Db00022
Protein chemical formula
Not Available
Protein average weight
31000.0 Da
Sequences
>DB00022 sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Download FASTA Format
Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Interferon Alfa-2b, Recombinantunknown43K1W2T1M698530-12-2Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PegintronInjection, powder, lyophilized, for solution80 ug/0.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegIntronInjection, powder, lyophilized, for solution150 ug/0.5mLSubcutaneousMerck Sharp & Dohme Corp.2013-12-182013-12-18Us
PegIntronInjection, powder, lyophilized, for solution80 ug/0.5mLSubcutaneousMerck Sharp & Dohme Corp.2013-12-182013-12-18Us
PegintronKit150 ug/0.5mLMerck Sharp & Dohme Limited2001-01-192016-03-06Us
PegintronKit120 ug/0.5mLMerck Sharp & Dohme Limited2014-08-11Not applicableUs
PegintronKit50 ug/0.5mLMerck Sharp & Dohme Limited2001-01-192016-03-06Us
PegintronInjection, powder, lyophilized, for solution150 ug/0.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegintronInjection, powder, lyophilized, for solution50 ug/0.5mLSubcutaneousMerck Sharp & Dohme Limited2001-01-19Not applicableUs
PegIntronInjection, powder, lyophilized, for solution50 ug/0.5mLSubcutaneousMerck Sharp & Dohme Corp.2013-12-182013-12-18Us
PegintronKit80 ug/0.5mLMerck Sharp & Dohme Limited2014-08-11Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
PegetronPeginterferon alfa-2b (80 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2002-08-132013-01-23Canada
PegetronPeginterferon alfa-2b (120 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2004-09-17Not applicableCanada
PegetronPeginterferon alfa-2b (150 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2002-08-132017-04-04Canada
PegetronPeginterferon alfa-2b (120 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2002-08-132013-01-23Canada
PegetronPeginterferon alfa-2b (100 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2004-09-17Not applicableCanada
PegetronPeginterferon alfa-2b (50 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2002-08-132017-04-04Canada
PegetronPeginterferon alfa-2b (100 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2002-08-132013-01-23Canada
PegetronPeginterferon alfa-2b (150 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2004-09-17Not applicableCanada
PegetronPeginterferon alfa-2b (80 mcg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2004-09-17Not applicableCanada
Victrelis TriplePeginterferon alfa-2b (120 mcg) + Boceprevir (200 mg) + Ribavirin (200 mg)Capsule; Powder, for solutionOral; SubcutaneousMerck Ltd.2011-08-162016-09-02Canada
International/Other Brands
PEG-Intron (Schering Corp)
Categories
UNII
G8RGG88B68
CAS number
215647-85-1

Pharmacology

Indication

Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.

Associated Conditions
Pharmacodynamics

Peginterferon alfa-2b inhibits viral replication in infected cells, suppresses cell proliferation, induces apoptosis, and exerts an anti-angiogenic effect [Label]. Exerts immunomodulatory effects such as enhancement of the phagocytic activity of macrophages, activation of NK cells, stimulation of cytotoxic T-lymphocytes, and the upregulation of the Th1 T-helper cell subset. Also increases concentrations of effector proteins such as serum neopterin and 2'5' oligoadenylate synthetase, raises body temperature, and causes reversible decreases in leukocyte and platelet counts.

Mechanism of action

Peginterferon alfa-2b is derived from recombinant human interferon's alfa-2b moeity [Label]. It binds to and activates human type 1 interferon receptors causing them to dimerize. This activates the JAK/STAT pathway. Activation of the JAK/STAT pathway increases expression of multiple genes in multiple tissues involved in the innate antiviral response. Peginterferon alfa-2b may also acitvate the nuclear factor κB pathway.

TargetActionsOrganism
AInterferon alpha/beta receptor 1
agonist
Human
AInterferon alpha/beta receptor 2
agonist
Human
Absorption

Peginterferon alfa-2b reaches peak plasma concentration 15-44 hours after subcutaneous administration [Label]. The mean absorption half-life is 4.6 hours. After multiple doses the bioavailability of Peginterferon alfa-2b increases with trough concentrations at week 48 3-fold higher than those at week 4.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Renal elimination accounts for 30% of Peginterferon alfa-2b elimination [Label].

Half life

The mean half-life of elimination of Peginterferon alfa-2b is 40 hours in a range of 22-60 hours [Label].

Clearance

The estimated apparent clearance of Peginterferon alfa-2b is 22 milliters per hour per kilogram [Label].

Toxicity

Peginterferon alfa-2b may manifest neuropsychiatric complications include suicide, suicidal ideation, homicidal ideation, depression, relapse of drug addiction, and drug overdose [Label]. Hypertension, supraventricular arrhythmias, chest pain, and myocardial infarction have been observed in patients using Peginterferon alfa-2b. Peginterferon alfa-2b may produce myelosuppression as well as the development or aggravation of autoimmune disorders including myositis, hepatitis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, interstitial nephritis, thyroiditis, and systemic lupus erythematosus. Peginterferon alfa-2b causes or aggravates hypothyroidism and hyperthyroidism. Hyperglycemia, hypoglycemia, and diabetes mellitus have been observed to develop in patients treated with Peginterferon alfa-2b. Peginterferon alfa-2b may decrease or produce loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema and serous retinal detachment. Peginterferon mayy be related to increased ischemic and hemorrhagic cerebrovascular events. Patients with cirrhosis on Peginterferon alfa-2b are at risk of hepatic decompensation. Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension and sarcoidosis may be induced or aggravated by Peginterferon alfa-2b. Serious and severe infections (bacterial, viral, or fungal) have been reported during treatment with Peginterferon alfa-2b. Ulcerative and hemorrhagic/ischemic colitis have been observed within 12 weeks of starting Peginterferon alfa-2b treatment. Pancreatitis and peripheral nephropathy have also been reported. Peginterferon alfa-2b is associated with growth inhibition in pediatric patients. Use of Peginterferon alfa-2b while pregant may result in delopmental abnormalities or death of the fetus.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Interferon lambda-3---(T;T) / (C;T) / (G;G) / (G;T)C > TEffect Directly StudiedPatients with this genotype in IFNL3 have a reduced likelihood of achieving sustained virologic response to peginterferon alfa-2b therapy.Details

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Peginterferon alfa-2b.
(S)-WarfarinThe risk or severity of bleeding can be increased when (S)-Warfarin is combined with Peginterferon alfa-2b.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with 2-Methoxyethanol.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Peginterferon alfa-2b.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Peginterferon alfa-2b.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Peginterferon alfa-2b.
6-O-benzylguanineThe serum concentration of 6-O-benzylguanine can be increased when it is combined with Peginterferon alfa-2b.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Peginterferon alfa-2b.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Peginterferon alfa-2b.
8-azaguanineThe serum concentration of 8-azaguanine can be increased when it is combined with Peginterferon alfa-2b.
Food Interactions
Not Available

References

General References
  1. Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [PubMed:25585348]
  2. Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [PubMed:28497432]
  3. American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
External Links
UniProt
P01563
PubChem Substance
46506669
ChEMBL
CHEMBL1201561
Therapeutic Targets Database
DAP001279
PharmGKB
PA164784024
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Peginterferon_alfa-2b
ATC Codes
L03AB60 — Peginterferon alfa-2b, combinationsL03AB10 — Peginterferon alfa-2b
AHFS Codes
  • 08:18.20 — Interferons
FDA label
Download (1.69 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentMelanoma2
1CompletedDiagnosticChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentImpaired Renal Function1
1CompletedTreatmentMelanoma2
1Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Infection, Human Immunodeficiency Virus I1
1TerminatedTreatmentHepatitis C Viral Infection1
1TerminatedTreatmentRenal Cancers1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnDiagnosticChronic Hepatitis C Virus (HCV) Infection1
1, 2Active Not RecruitingTreatmentMetastatic Melanoma1
1, 2CompletedTreatmentHepatitis C Viral Infection1
1, 2CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2RecruitingTreatmentMelanoma / Renal Cell Adenocarcinoma1
1, 2TerminatedTreatmentCancer of the Ovary / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2TerminatedTreatmentHepatitis C Viral Infection1
2Active Not RecruitingTreatmentAdvanced Cholangiocarcinoma1
2Active Not RecruitingTreatmentChildhood Craniopharyngioma1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
2Active Not RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma (SCC) / Squamous Cell Carcinoma of Skin1
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection9
2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection1
2CompletedTreatmentHealth Care Evaluation / Health Care Quality1
2CompletedTreatmentHepatitis B Chronic Infection1
2CompletedTreatmentHepatitis C Infection1
2CompletedTreatmentHepatitis C Viral Infection3
2CompletedTreatmentHepatitis C Viral Infection / Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHepatitis C Virus (HCV) Infection / Liver Cirrhosis, Experimental1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentLeukemias1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMelanoma2
2CompletedTreatmentPlexiform Neurofibroma1
2RecruitingTreatmentJuvenile Pilocytic Astrocytomas / Optic Pathway Gliomas1
2TerminatedTreatmentAnemias / Hypoxemia / Liver Diseases1
2TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection2
2TerminatedTreatmentChronic Myeloid Leukemia (CML)1
2TerminatedTreatmentLeukemia, Myeloid, Philadelphia-Positive1
2TerminatedTreatmentLeukemias1
2Unknown StatusTreatmentMelanoma1
2WithdrawnTreatmentChronic Myeloid Leukemia (CML)1
2, 3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis, Liver1
2, 3CompletedTreatmentHepatitis C Viral Infection1
2, 3CompletedTreatmentHepatitis / Hepatitis C Viral Infection1
2, 3TerminatedOtherChronic Hepatitis C Virus (HCV) Infection / Hepacivirus1
2, 3TerminatedTreatmentMelanoma1
2, 3WithdrawnTreatmentChronic Hepatitis C Virus (HCV) Infection1
3Active Not RecruitingTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Bone Sarcomas1
3CompletedPreventionHepatocellular,Carcinoma1
3CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentChronic Hepatitis C Genotype 11
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection19
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis, Liver1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Fibrosis / Hepatitis / Liver Cirrhosis1
3CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection / Liver Cirrhosis2
3CompletedTreatmentChronic Myeloid Leukemia (CML)1
3CompletedTreatmentCoinfection / Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHepatitis B Chronic Infection / Hepatitis D, Chronic1
3CompletedTreatmentHepatitis B, Chronic (CHB)1
3CompletedTreatmentHepatitis C Viral Infection6
3CompletedTreatmentHepatitis / Hepatitis C Viral Infection / Hepatitis C/ Human Immunodeficiency Virus Coinfection1
3CompletedTreatmentMelanoma / Neoplasms Metastasis1
3RecruitingTreatmentHepatitis B Chronic Infection1
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection3
3TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection / Liver Cirrhosis1
3TerminatedTreatmentHepatitis B Chronic Infection1
3Unknown StatusTreatmentGenotype 4 Chronic Hepatitis C Infection1
3Unknown StatusTreatmentHepatitis B Chronic Infection1
3WithdrawnTreatmentChronic Hepatitis C Virus (HCV) Infection3
3WithdrawnTreatmentHepatitis C Viral Infection1
4Active Not RecruitingNot AvailableHepatitis C Infection / Human Immunodeficiency Virus (HIV)1
4CompletedNot AvailableHepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted1
4CompletedTreatmentAntiviral Agents / Chronic Liver Diseases (CLD) / Hepatitis C Virus (HCV) Infection / Therapeutic Uses / Virus Hepatitis1
4CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection4
4CompletedTreatmentHepatitis B Chronic Infection1
4CompletedTreatmentHepatitis C Viral Infection2
4CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
4CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
4RecruitingTreatmentHepatitis B Chronic Infection1
4TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection3
4TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection / Hepacivirus / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentChronic Hepatitis C Virus (HCV) Infection / End Stage Renal Disease (ESRD)1
4Unknown StatusTreatmentHepatitis C Infection1
4WithdrawnTreatmentHepatitis C Viral Infection1
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection10
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Genotype 1 / HCV-11
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepacivirus4
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection10
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Virus (HCV) Infection1
Not AvailableCompletedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Substance Abuse, Intravenous1
Not AvailableCompletedNot AvailableHepatitis C Viral Infection2
Not AvailableCompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingNot AvailableViral Hepatitis B1
Not AvailableRecruitingTreatmentHepatitis B Chronic Infection1
Not AvailableTerminatedNot AvailableChronic Hepatitis C Virus (HCV) Infection1
Not AvailableTerminatedNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepacivirus1
Not AvailableTerminatedTreatmentMalignant Lymphomas1
Not AvailableUnknown StatusBasic ScienceChronic HCV Infection / Nonalcoholic Steatohepatitis1
Not AvailableUnknown StatusTreatmentHepatitis B Chronic Infection1
Not AvailableWithdrawnNot AvailableChronic Hepatitis C Virus (HCV) Infection / Hepatitis C Viral Infection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Physicians Total Care Inc.
  • Schering Corp.
  • Schering-Plough Inc.
  • Vetter Pharma Fertigung GmbH and Co. KG
Dosage forms
FormRouteStrength
Capsule; powder, for solutionOral; Subcutaneous
Injection, powder, lyophilized, for solutionSubcutaneous120 ug/0.5mL
Injection, powder, lyophilized, for solutionSubcutaneous150 ug/0.5mL
Injection, powder, lyophilized, for solutionSubcutaneous50 ug/0.5mL
Injection, powder, lyophilized, for solutionSubcutaneous80 ug/0.5mL
Kit120 ug/0.5mL
Kit150 ug/0.5mL
Kit50 ug/0.5mL
Kit80 ug/0.5mL
Kit120 ug/0.1mL
Kit40 ug/0.1mL
Kit60 ug/0.1mL
Powder, for solutionSubcutaneous118.4 mcg
Powder, for solutionSubcutaneous177.6 mcg
Powder, for solutionSubcutaneous222 mcg
Powder, for solutionSubcutaneous74 mcg
Prices
Unit descriptionCostUnit
Peg-Intron Redipen Pak 4 4 50 mcg/0.5ml Kit Box2428.8USD kit
Peg-Intron Redipen 150 mcg/0.5ml Kit702.87USD kit
Peg-Intron 150 mcg Kit671.74USD kit
Peg-Intron Redipen 120 mcg/0.5ml Kit669.39USD kit
Peg-Intron redipen 150 mcg640.61USD redipen
Peg-Intron redipen 150 mcg 4pk640.6USD redipen
Peg-Intron 120 mcg Kit639.74USD kit
Peg-Intron Redipen 80 mcg/0.5ml Kit637.49USD kit
Peg-Intron redipen 120 mcg610.09USD redipen
Peg-Intron 80 mcg Kit609.26USD kit
Peg-Intron 50 mcg/0.5ml Kit607.19USD kit
Peg-Intron redipen 80 mcg581.02USD redipen
Peg-Intron 50 mcg kit553.4USD kit
Peg-Intron redipen 50 mcg553.4USD redipen
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341567No2008-02-192025-02-19Canada
CA2329474No0002-02-262016-10-31Canada

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)61 °CBeldarrain, A. et al., Biochemistry 38:7865-7873 (1999)
isoelectric point5.99Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR2 to form the type I interferon receptor. Receptor for interferons alpha and beta. Binding to type I IFNs triggers tyrosine phosphorylation of a number of proteins including JA...
Gene Name
IFNAR1
Uniprot ID
P17181
Uniprot Name
Interferon alpha/beta receptor 1
Molecular Weight
63524.81 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [PubMed:15898717]
  4. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [PubMed:19955815]
  5. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [PubMed:16953837]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Type i interferon receptor activity
Specific Function
Associates with IFNAR1 to form the type I interferon receptor. Receptor for interferons alpha and beta. Involved in IFN-mediated STAT1, STAT2 and STAT3 activation. Isoform 1 and isoform 2 are direc...
Gene Name
IFNAR2
Uniprot ID
P48551
Uniprot Name
Interferon alpha/beta receptor 2
Molecular Weight
57758.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H: Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem. 2005 May-Jun;16(3):518-27. [PubMed:15898717]
  4. Ishii K, Shinohara M, Sawa M, Kogame M, Higami K, Sano M, Morita T, Sumino Y: Interferon alpha receptor 2 expression by peripheral blood monocytes in patients with a high viral load of hepatitis C virus genotype 1 showing substitution of amino Acid 70 in the core region. Intervirology. 2010;53(2):105-10. doi: 10.1159/000264200. Epub 2009 Dec 3. [PubMed:19955815]
  5. Yano H, Ogasawara S, Momosaki S, Akiba J, Kojiro S, Fukahori S, Ishizaki H, Kuratomi K, Basaki Y, Oie S, Kuwano M, Kojiro M: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006 Oct;26(8):964-75. [PubMed:16953837]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
The FDA label states that single doses of this agent may not affect the CYP1A2 enzyme, however, the effect of multiple doses has not been studied.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Gupta SK, Kolz K, Cutler DL: Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol. 2011 Jun;67(6):591-9. doi: 10.1007/s00228-010-0972-5. Epub 2010 Dec 16. [PubMed:21161196]
  2. Peg-interferon alfa-2b FDA label [File]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Brennan BJ, Xu ZX, Grippo JF: Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol. 2013 Feb;75(2):497-506. doi: 10.1111/j.1365-2125.2012.04373.x. [PubMed:22765278]
  2. Aids info document [Link]
  3. Sylatron FDA label [File]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2018 07:44